[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erosive-esophagitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erosive-esophagitis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100382135","real-life-study-of-changes-of-gastroesophageal-reflux-disease-manifestations-due-to-behavioural-and-diet-adherence-100382135",false,"NCT04255693","Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","Inclusion Criteria:\n\n* willingness to participate (based on the signed informed consent form);\n* presence of gastroesophageal reflux disease, based on the following: a) typical symptoms, like heartburn and\u002For regurgitation (for primary selection, symptoms should be present at least weekly, be actual for at least 3 months prior to the enrolment, and the patient should report the history of symptoms which lasts for at least 6 months); b) previous response to the intake of proton pump inhibitors; c) data of 24-hours oesophageal pH-impedance monitoring with detected pathological gastroesophageal reflux according to the Lyon consensus definitions;\n\nExclusion Criteria:\n\n* pregnant or breast-feeding females;\n* abdominal or chest surgery (except appendectomy or cholecystectomy in case they are not followed by adhesive disease of the abdominal organs);\n* constant use of non-steroidal anti-inflammatory agents (NSAIDs), sporadic use of NSAIDs will be allowed in case the course of treatment was discontinued at least 2 weeks prior to the enrolment, in case that constant use of NSAIDs happen to be necessary after the enrolment, the patients may continue in the study but doses, frequency and duration of treatment should be carefully documented;\n* history or current evidence of cancer of any aetiology and location besides skin cancer in situ successfully treated before the enrolment;\n* severe patient's conditions which may lead to misinterpretation of data, or in case of patient's enrolment may put him at risk of exacerbation of co-morbid conditions, or in cases when on discretion of the investigator patient's condition would not allow him to complete the course of the observation. These conditions include, but not limited to: heart failure (class III-IV by NYHA), uncontrolled hypertension, severe neurological disorders, decompensated liver cirrhosis (Child-Pugh B or C), severe depression or other psychological disorders;\n* the patient may stop his participation in the study at any time by informing the site personal about his\u002Fher decision to withdraw the consent.","ALL","18 Years","80 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease",[26,27,28,29,30,31],"Gastroesophageal Reflux Disease","GERD","Gastroesophageal Erosion","Erosive Esophagitis","Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease",[27,33,34,35,36,37,38],"NERD","erosive esophagitis","diet","food","adherence","influence","RECRUITING","2025-08-01",{"date":42,"type":43},"2025-08-03","ACTUAL",{"date":45,"type":43},"2020-01-31",{"date":47,"type":20},"2027-12-31",{"name":49,"class":50},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":51},"100566835","a-study-of-the-safety-of-vonoprazan-exposure-in-pregnant-women-and-their-offspring-100566835","NCT06660342","A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Inclusion Criteria:\n\n* Women 15 to 50 years of age.\n* Currently or recently pregnant.\n* Consent to participate.\n* Authorization for her health care provider(s) (HCP\\[s\\]) to provide data to the registry.\n* Exposed cohort: Exposure to at least one dose of vonoprazan during pregnancy.\n* Unexposed cohort: Unexposed to vonoprazan and diagnosis of any condition for which vonoprazan may be prescribed.\n\nExclusion Criteria:\n\n* Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).\n* Exposure to known tetratogens and\u002For investigational medications during pregnancy.\n* Lost to follow-up.","FEMALE","15 Years","50 Years",{"count":63,"type":20},728,"12 Months","OBSERVATIONAL","The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.",[29,68,69,70],"Heartburn","Symptomatic Non-erosive Gastroesophageal Reflux Disease","Helicobacter Pylori Infection",[29,68,69,70,72,73,74],"Pregnant Women","Fetal","Infant","2025-05-21",{"date":77,"type":43},"2025-05-22",{"date":79,"type":43},"2025-05-15",{"date":81,"type":20},"2034-09",{"name":83,"class":84},"Phathom Pharmaceuticals, Inc.","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100571465","phase-4-indonesian-study-of-vonoprazan-vs-esomeprazole-in-erosive-esophagitis-100571465","NCT06720610","Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis","Comparison of the Effectiveness of Vonoprazan and Esomeprazole in Improving Initial Symptoms in Patients with Erosive Esophagitis: a Double-Blind Randomized Trial","INVEST","Inclusion Criteria:\n\n* Patients aged \\>18 years with a GERD-Q score of 8.\n* Diagnosed with erosive esophagitis by endoscopy. (Los Angeles Classification A-D)\n* Patients are willing to undergo a series of therapeutic management.\n\nExclusion Criteria:\n\n* Patients with a history of allergy to PCAB or PPI groups.\n* Patients with gastric and\u002For duodenal ulcers.\n* Patients with Helicobacter pylori infection.\n* Patients with a history of significant systemic disease disorders affecting the esophagus and stomach.\n* Patients with a history of malignant disease related to the esophagus and\u002For stomach.\n* Patients with a history of esophageal and\u002For gastric surgery.\n* Pregnant patients",{"count":94,"type":20},216,[96],"PHASE4","The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities. The main questions it aims to answer are:\n\nHow does the effectiveness of Vonoprazan compare with Esomeprazole in improving early symptoms of erosive esophagitis patients in the Indonesian population?\n\nResearchers will compare drug vonoprazan to a esomeprazole with a look-alike packaging to see their effect to reduce early symptoms of erosive esophagitis.\n\nParticipants will:\n\n* Take drug vonoprazan 20mg or esomeprazole 40mg one time every day for 2 weeks\n* Visit the clinic once every weeks for followup (Gastro Esophageal Reflux Disease-Quetionnaire measurement)\n* Keep a diary of their adverse effect occurence and every variable data based on Gastro Esophageal Reflux Disease-Questionnaire.",[29],[34,100,101,102],"vonoprazan","esomeprazole","gerd-q","NOT_YET_RECRUITING","2024-12-12",{"date":106,"type":43},"2024-12-17",{"date":108,"type":20},"2024-12-09",{"date":110,"type":20},"2025-06-27",{"name":112,"class":50},"Indonesia University",5]